Sign in
TCF Stock Price, Chart, Stats & News
Theracryf Plc
Save
Theracryf Plc (TCF) does not currently pay a dividend.
4.08M
Market cap
–
Current P/E
–
Forward P/E
TCF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Theracryf Plc operates as a clinical-stage biotechnology firm, dedicated to advancing treatments for oncological diseases and various brain disorders affecting behavior. Its primary therapeutic asset, SFX-01, is currently progressing through Phase II clinical trials for metastatic breast cancer. Additionally, SFX-01 is in Phase I trials for neurodevelopmental conditions and glioblastoma, and is undergoing preclinical investigation for rhabdomyosarcoma.
Similar securities
Based on sector and market capitalization
Report issue